$NAMS
NewAmsterdam Pharma Co N.V.

2024 Q2 Form 10-Q Financial Statement

#000095017024055767 Filed on May 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1 2023 Q1
Revenue $2.279M $1.401M $8.629M
YoY Change -76.17% -83.76%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $16.48M $14.45M $8.062M
YoY Change 20.24% 79.27% 2239.39%
% of Gross Profit
Research & Development $38.38M $42.43M $40.42M
YoY Change -47.33% 4.97%
% of Gross Profit
Depreciation & Amortization $15.00K $9.000K
YoY Change 66.67%
% of Gross Profit
Operating Expenses $54.85M $56.88M $48.48M
YoY Change -36.66% 17.33% 13968.25%
Operating Profit -$52.58M -$55.48M -$39.85M
YoY Change 23.76% 39.22%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$39.01M -$93.77M -$42.02M
YoY Change -48.06% 123.16% -3134.62%
Income Tax
% Of Pretax Income
Net Earnings -$39.01M -$93.77M -$42.02M
YoY Change -48.06% 123.16% -3134.62%
Net Earnings / Revenue -1711.58% -6692.86% -486.94%
Basic Earnings Per Share -$0.41 -$1.06 -$0.51
Diluted Earnings Per Share -$0.41 -$1.06 -$0.51
COMMON SHARES
Basic Shares Outstanding 89.98M 89.27M 81.63M
Diluted Shares Outstanding 94.71M 88.38M 81.63M

Balance Sheet

Concept 2024 Q2 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $430.7M $481.1M $441.3M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables $2.134M $3.985M
Total Short-Term Assets $445.4M $487.8M
YoY Change 14.41%
LONG-TERM ASSETS
Property, Plant & Equipment $234.0K $101.0K
YoY Change 108.93%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.338M $641.0K
YoY Change -98.36%
TOTAL ASSETS
Total Short-Term Assets $445.4M $487.8M
Total Long-Term Assets $1.338M $641.0K
Total Assets $446.7M $488.5M
YoY Change -5.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.275M $8.536M
YoY Change -74.71%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $45.31M $59.73M
YoY Change 18.19%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $45.31M $59.73M
Total Long-Term Liabilities
Total Liabilities $59.25M $76.66M
YoY Change 21.33%
SHAREHOLDERS EQUITY
Retained Earnings -$449.7M -$410.7M
YoY Change
Common Stock $832.8M $818.1M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $387.4M $411.8M $398.4M
YoY Change
Total Liabilities & Shareholders Equity $446.7M $488.5M
YoY Change -5.18%

Cashflow Statement

Concept 2024 Q2 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$39.01M -$93.77M -$42.02M
YoY Change -48.06% 123.16% -3134.62%
Depreciation, Depletion And Amortization $15.00K $9.000K
YoY Change 66.67%
Cash From Operating Activities -$54.60M -$31.86M
YoY Change 71.36% 7993.63%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$385.0K -$7.000K
YoY Change 5400.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 198.2M 2.392M
YoY Change 8185.12% -5415.56%
NET CHANGE
Cash From Operating Activities -54.60M -31.86M
Cash From Investing Activities -385.0K -7.000K
Cash From Financing Activities 198.2M 2.392M
Net Change In Cash 143.2M -29.48M
YoY Change -585.76% 6619.7%
FREE CASH FLOW
Cash From Operating Activities -$54.60M -$31.86M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001936258
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-41562
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
NewAmsterdam Pharma Company N.V.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
P7
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
Gooimeer 2-35
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Naarden
CY2024Q1 dei Entity Address Country
EntityAddressCountry
NL
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
1411 DC
CY2024Q1 dei City Area Code
CityAreaCode
+31
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
(0) 35 206 2971
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
89976538
CY2024Q1 us-gaap Cash
Cash
481147000
CY2023Q4 us-gaap Cash
Cash
340450000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6675000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6341000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
487822000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
346791000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
101000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
46000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
38000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
55000
CY2024Q1 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
486000
CY2023Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
170000
CY2024Q1 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
16000
CY2023Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
35000
CY2024Q1 us-gaap Assets
Assets
488463000
CY2023Q4 us-gaap Assets
Assets
347097000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
8536000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
16923000
CY2024Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
9970000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
11398000
CY2024Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
8116000
CY2023Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
8942000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
43000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
60000
CY2024Q1 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
33061000
CY2023Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
12574000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
59726000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
49897000
CY2024Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
444000
CY2023Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1019000
CY2024Q1 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
16490000
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
7788000
CY2024Q1 us-gaap Liabilities
Liabilities
76660000
CY2023Q4 us-gaap Liabilities
Liabilities
58704000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.12
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.12
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
89720836
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
89720836
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
82469768
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
82469768
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
11113000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
10173000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
807008000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
590771000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-410740000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-316973000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4422000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
4422000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
411803000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
288393000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
488463000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
347097000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1401000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8629000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42430000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
40420000
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
14453000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
8062000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
56883000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
48482000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-55482000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-39853000
CY2024Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
3083000
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
943000
CY2024Q1 nams Change In Fair Value Of Earnout And Warrants
ChangeInFairValueOfEarnoutAndWarrants
38950000
CY2023Q1 nams Change In Fair Value Of Earnout And Warrants
ChangeInFairValueOfEarnoutAndWarrants
6175000
CY2024Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2418000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
3067000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-93767000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-42018000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-93767000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42018000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.06
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.06
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
430066000
CY2023Q1 nams Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
2698000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7663000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42018000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
398409000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
288393000
CY2024Q1 nams Issuance Of Ordinary Shares And Pre Funded Warrants Net Of Issuance Cost
IssuanceOfOrdinarySharesAndPreFundedWarrantsNetOfIssuanceCost
189966000
CY2024Q1 nams Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
19795000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-549000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7965000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-93767000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
411803000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-93767000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-42018000
CY2024Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
15000
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
9000
CY2024Q1 nams Noncash Rent Expense
NoncashRentExpense
1000
CY2023Q1 nams Noncash Rent Expense
NoncashRentExpense
2000
CY2024Q1 nams Change In Fair Value Of Derivative Earnout And Warrants
ChangeInFairValueOfDerivativeEarnoutAndWarrants
38950000
CY2023Q1 nams Change In Fair Value Of Derivative Earnout And Warrants
ChangeInFairValueOfDerivativeEarnoutAndWarrants
6175000
CY2024Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-2418000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
3067000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
7918000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
7616000
CY2024Q1 nams Increase Decrease In Prepayments And Other Receivables
IncreaseDecreaseInPrepaymentsAndOtherReceivables
-956000
CY2023Q1 nams Increase Decrease In Prepayments And Other Receivables
IncreaseDecreaseInPrepaymentsAndOtherReceivables
1413000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-8311000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2920000
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-1381000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
6997000
CY2024Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1401000
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3244000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-54602000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31863000
CY2024Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
385000
CY2023Q1 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
7000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-385000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7000
CY2024Q1 nams Proceeds From Offering Of Ordinary Shares And Pre Funded Warrants Net Of Issuance Costs
ProceedsFromOfferingOfOrdinarySharesAndPreFundedWarrantsNetOfIssuanceCosts
190481000
CY2024Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
515000
CY2024Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
8763000
CY2023Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2392000
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
440000
CY2024Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
989000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
198180000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2392000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
143193000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-29478000
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-2496000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3062000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
340450000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
467728000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
481147000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
441312000
CY2024Q1 nams Receivable Related To Exercise Of Warrants
ReceivableRelatedToExerciseOfWarrants
1271000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.12
CY2023Q1 nams License Revenue Attributed From License Performance Obligations
LicenseRevenueAttributedFromLicensePerformanceObligations
5385000
CY2024Q1 nams License Revenue Attributed From R And D Performance Obligations
LicenseRevenueAttributedFromRAndDPerformanceObligations
1401000
CY2023Q1 nams License Revenue Attributed From R And D Performance Obligations
LicenseRevenueAttributedFromRAndDPerformanceObligations
3244000
CY2024Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1401000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8629000
CY2024Q1 nams Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
420000
CY2023Q4 nams Prepaid Research And Development Costs Current
PrepaidResearchAndDevelopmentCostsCurrent
2337000
CY2024Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2122000
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
2123000
CY2024Q1 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
148000
CY2023Q4 us-gaap Value Added Tax Receivable Current
ValueAddedTaxReceivableCurrent
1006000
CY2024Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
3985000
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
875000
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6675000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6341000
CY2024Q1 nams Accrued Research And Development Materials And Services Current
AccruedResearchAndDevelopmentMaterialsAndServicesCurrent
7190000
CY2023Q4 nams Accrued Research And Development Materials And Services Current
AccruedResearchAndDevelopmentMaterialsAndServicesCurrent
5945000
CY2024Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1105000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3384000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1675000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2069000
CY2024Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
9970000
CY2023Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
11398000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
15783509
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.98
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4096148
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.81
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
546403
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.27
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
19333254
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.18
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M18D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
279666000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6134169
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.64
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
110454000
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
5.9
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
4.82
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
8000000
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y1M6D
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.039
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.04
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.412
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.385
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments
0
CY2024Q1 nams Volatility Ordinary Shares
VolatilityOrdinaryShares
0.10
CY2024Q1 nams Increase In Volatility Weight Percentage Of Ordinary Share Per Calendar Quarter
IncreaseInVolatilityWeightPercentageOfOrdinarySharePerCalendarQuarter
0.05
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7918000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7616000
CY2024Q1 nams Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Unrecognized Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsUnrecognizedCompensationCost
41500000
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P3Y3M18D
CY2021Q3 nams Underlying Ordinary Shares1
UnderlyingOrdinaryShares1
838806
CY2023 nams Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Liability For Unvested Ordinary Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsLiabilityForUnvestedOrdinaryShares
100000
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
608779
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
608779
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
558048
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
519999
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-93767000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-42018000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
88380230
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
88380230
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
81634428
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
81634428
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.06
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.06
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.51
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.51
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
22327927
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
19906520
CY2024Q1 nams Estimated Maximum Cancellation Fees
EstimatedMaximumCancellationFees
19200000
CY2024Q1 nams Percentage Of Development Costs Incurred
PercentageOfDevelopmentCostsIncurred
0.50
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-055767-index-headers.html Edgar Link pending
0000950170-24-055767-index.html Edgar Link pending
0000950170-24-055767.txt Edgar Link pending
0000950170-24-055767-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nams-20240331.htm Edgar Link pending
nams-20240331.xsd Edgar Link pending
nams-ex31_1.htm Edgar Link pending
nams-ex31_2.htm Edgar Link pending
nams-ex32_1.htm Edgar Link pending
nams-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nams-20240331_htm.xml Edgar Link completed
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending